| Market Cap | 102.41M | P/E | - | EPS this Y | 17.30% | Ern Qtrly Grth | - |
| Income | -59.69M | Forward P/E | -1.83 | EPS next Y | -33.90% | 50D Avg Chg | -12.00% |
| Sales | 1M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -22.00% |
| Dividend | N/A | Price/Book | 2.44 | EPS next 5Y | - | 52W High Chg | -69.00% |
| Recommedations | 2.20 | Quick Ratio | 9.34 | Shares Outstanding | 53.15M | 52W Low Chg | 12.00% |
| Insider Own | 0.63% | ROA | -51.01% | Shares Float | 33.92M | Beta | 1.77 |
| Inst Own | 33.96% | ROE | -143.61% | Shares Shorted/Prior | 431.41K/480.13K | Price | 3.07 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 108,772 | Target Price | 10.50 |
| Oper. Margin | -6,109.80% | Earnings Date | May 9 | Volume | 31,559 | Change | -3.15% |
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
| HC Wainwright & Co. | Buy | Mar 22, 24 |
| Piper Sandler | Overweight | Mar 5, 24 |
| HC Wainwright & Co. | Buy | Feb 26, 24 |
| TD Cowen | Outperform | Dec 27, 23 |
| HC Wainwright & Co. | Buy | Aug 14, 23 |
| Jefferies | Hold | Jun 20, 23 |
| HC Wainwright & Co. | Buy | May 23, 23 |
| HC Wainwright & Co. | Buy | May 15, 23 |
| Oppenheimer | Outperform | Apr 12, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Wills Robert James | Director Director | Oct 19 | Buy | 4.93 | 15,000 | 73,950 | 15,000 | 10/21/22 |
| Pasternak Richard C | Director Director | Oct 20 | Buy | 5.20 | 10,000 | 52,000 | 10,000 | 10/21/22 |
| Liebert Debra K. | Director Director | Oct 20 | Buy | 5.28 | 14,000 | 73,920 | 4,000 | 10/21/22 |
| TOMSICEK MICHAEL JOHN | Director Director | Oct 19 | Buy | 5.32 | 15,000 | 79,800 | 15,000 | 10/21/22 |
| RTW INVESTMENTS, LP | 10% Owner 10% Owner | Sep 07 | Buy | 8.71 | 1,557,346 | 13,564,484 | 4,315,102 | 09/09/22 |
| RTW INVESTMENTS, LP | 10% Owner 10% Owner | Sep 07 | Sell | 8.71 | 1,557,346 | 13,564,484 | 4,315,102 | 09/09/22 |
| TRUEX PAUL F | Director Director | May 31 | Option | 1.72 | 76,780 | 132,062 | 76,780 | 06/01/22 |
| TRUEX PAUL F | Director Director | May 31 | Buy | 5.6 | 5,000 | 28,000 | 81,780 | 06/01/22 |